TY - JOUR
KW - Antigen-Antibody Complex/metabolism
KW - Blood-Brain Barrier/metabolism
KW - Drug Overdose/prevention & control
KW - Fentanyl
KW - Heroin
KW - Humans
KW - Opiate Substitution Treatment
KW - opioid epidemic
KW - Opioid-Related Disorders/drug therapy
KW - Oxycodone
KW - Vaccines/therapeutic use
KW - Antibody
KW - GMP
KW - Opioid
KW - Translation
KW - Vaccine
AU - M. Pravetoni
AU - S. D. Comer
A1 - 
AD - University of Minnesota Medical School, Departments of Pharmacology and Medicine, Minneapolis, MN, USA; Hennepin Healthcare Research Institute, Minneapolis, MN, USA. Electronic address: prave001@umn.edu.; Columbia University Irving Medical Center, Department of Psychiatry, The New York State Psychiatric Institute, New York, NY, USA.
BT - Neuropharmacology
C5 - Opioids & Substance Use
DO - 10.1016/j.neuropharm.2019.06.001
JF - Neuropharmacology
LA - eng
M1 - Journal Article
PB - Elsevier Ltd
PY - 2019
SN - 1873-7064; 0028-3908; 0028-3908
SP - 107662
T1 - Development of vaccines to treat opioid use disorders and reduce incidence of overdose
T2 - Neuropharmacology
TI - Development of vaccines to treat opioid use disorders and reduce incidence of overdose
U1 - Opioids & Substance Use
U2 - 31173759
U3 - 10.1016/j.neuropharm.2019.06.001
VL - 158
VO - 1873-7064; 0028-3908; 0028-3908
Y1 - 2019
Y2 - Nov 1
ER -